Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2026)

Bicycle Therapeutics has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $34.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 58.23% year-over-year to $34.3 million; the trailing twelve-month figure through Mar 2026 stood at $34.3 million (down 58.23% YoY), and the FY2025 full-year result was $35.5 million, down 61.18% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $34.3 million, down from $35.5 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $115.1 million in Q2 2023, with the low at $34.3 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $75.5 million across 5 years, with a median of $82.9 million in 2025.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue jumped 165.87% — and 2025, when it tumbled 61.18%.
• Bicycle Therapeutics' Non-Current Deffered Revenue stood at $41.5 million in 2022, then soared by 165.87% to $110.2 million in 2023, then decreased by 17.01% to $91.5 million in 2024, then slumped by 61.18% to $35.5 million in 2025, then declined by 3.29% to $34.3 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $34.3 million (Q1 2026), $35.5 million (Q4 2025), and $74.1 million (Q3 2025), per Business Quant data.